Cancer Therapy Due to Apoptosis: Galectin-9
AbstractDysregulation of apoptosis is a major hallmark in cancer biology that might equip tumors with a higher malignant potential and chemoresistance. The anti-cancer activities of lectin, defined as a carbohydrate-binding protein that is not an enzyme or antibody, have been investigated for over a century. Recently, galectin-9, which has two distinct carbohydrate recognition domains connected by a linker peptide, was noted to induce apoptosis in thymocytes and immune cells. The apoptosis of these cells contributes to the development and regulation of acquired immunity. Furthermore, human recombinant galectin-9, hG9NC (null), which lacks an entire region of the linker peptide, was designed to resist proteolysis. The hG9NC (null) has demonstrated anti-cancer activities, including inducing apoptosis in hematological, dermatological and gastrointestinal malignancies. In this review, the molecular characteristics, history and apoptosis-inducing potential of galectin-9 are described. View Full-Text
Share & Cite This Article
Fujita, K.; Iwama, H.; Oura, K.; Tadokoro, T.; Samukawa, E.; Sakamoto, T.; Nomura, T.; Tani, J.; Yoneyama, H.; Morishita, A.; Himoto, T.; Hirashima, M.; Masaki, T. Cancer Therapy Due to Apoptosis: Galectin-9. Int. J. Mol. Sci. 2017, 18, 74.
Fujita K, Iwama H, Oura K, Tadokoro T, Samukawa E, Sakamoto T, Nomura T, Tani J, Yoneyama H, Morishita A, Himoto T, Hirashima M, Masaki T. Cancer Therapy Due to Apoptosis: Galectin-9. International Journal of Molecular Sciences. 2017; 18(1):74.Chicago/Turabian Style
Fujita, Koji; Iwama, Hisakazu; Oura, Kyoko; Tadokoro, Tomoko; Samukawa, Eri; Sakamoto, Teppei; Nomura, Takako; Tani, Joji; Yoneyama, Hirohito; Morishita, Asahiro; Himoto, Takashi; Hirashima, Mitsuomi; Masaki, Tsutomu. 2017. "Cancer Therapy Due to Apoptosis: Galectin-9." Int. J. Mol. Sci. 18, no. 1: 74.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.